SwissNET - a Registry for Neuroendocrine Tumours in Switzerland (SwissNET)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||SwissNET - a Prospective Registry of Patients With Neuroendocrine Tumours in Switzerland|
- Tumor-related mortality [ Time Frame: Every 5 years ] [ Designated as safety issue: No ]
- Incidence of GEP-NET in Switzerland [ Time Frame: Every 5 years ] [ Designated as safety issue: No ]
- Effect of specific treatment strategies [ Time Frame: Every 5 years ] [ Designated as safety issue: No ]
|Study Start Date:||January 2008|
|Estimated Study Completion Date:||January 2028|
|Estimated Primary Completion Date:||January 2028 (Final data collection date for primary outcome measure)|
Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location or of a merkel cell carcinoma.
Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are generally classified as rare diseases. Little is known about their cell biology and their mechanistic regulation. During the last years, the incidence of GEP-NETs is continuously increasing worldwide. In parallel, novel treatment options are currently evaluated which may substantially improve prognosis of patients with NETs. Data on such tumours in Switzerland, however, is scarce and treatment strategies vary throughout the country.
To systematically and prospectively collect clinical information of patients with GEP-NETs in Switzerland based on a histologically confirmed diagnosis.
All NETs of both, gastrointestinal and pulmonary origin are included provided that patients have given informed consent. Data will be entered prospectively and anonymised in a specifically designed database. Contributing centres and general practitioners are visited by a study nurse, patient files are analysed and data is transferred to the database. In case of conflicting evidence, questions are resolved in collaboration with a review board of SwissNET. Evaluation of treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate) will take place within regular time frames.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01039922
|Contact: Attila Kollàr, MD||++41 31 632 21 email@example.com|
|Contact: Emanuel Christ, MD, PhD||++41 31 632 40 firstname.lastname@example.org|
|Div. of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital||Recruiting|
|Bern, Switzerland, 3010|
|Principal Investigator: Attila Kollàr, MD|
|Study Director:||Aurel Perren, MD||Institute of Pathology, University of Bern, Bern|